ADIENNE
ADIENNE is a privately held, founder-led biopharmaceutical company founded in 2004 and headquartered in Lugano, Switzerland, operating with 51–100 employees. Specific therapeutic focus, products, and pipeline were not retrievable from available data.
- Company typePrivate
- Founded2004
- HeadquartersLugano, Switzerland
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What ADIENNE does
ADIENNE is a privately held biopharmaceutical company headquartered in Lugano, Switzerland, founded in 2004. The company operates with a headcount in the 51–100 range and is led by founder and president Antonio Francesco Di Naro, indicating a founder-controlled governance structure that has persisted across the company's two-decade operating history.
The company's website (adienne.com) was inaccessible during data collection, presenting only a loading/verification message; consequently, the specific therapeutic areas, product portfolio, pipeline stage, manufacturing capabilities, and target indications of ADIENNE could not be verified from the primary source. Based on its firmographic profile (Swiss domicile, ~20-year operating history, biotech-relevant headcount, founder-led), ADIENNE conforms to the archetype of a European specialty biopharma focused on niche or rare-disease therapeutics, though no named products, candidates, or technology platform could be extracted from the input.
ADIENNE is a for-profit private company (no public ticker is recorded). No funding rounds, ownership structure, partnerships, or customer relationships are documented in the available input, and no information about revenue model, pricing, go-to-market strategy, or end markets could be confirmed. Investors examining ADIENNE should treat the firmographic profile as the only confirmed identity and pursue direct company outreach to validate product strategy, pipeline, and commercial status.
ADIENNE firmographics
Firmographics- Name
- ADIENNE
- Website
- https://adienne.com
- Company type
- Private
- Founded year
- 2004
- Headcount range
- 51–100 employees
- Short description
- ADIENNE is a privately held, founder-led biopharmaceutical company founded in 2004 and headquartered in Lugano, Switzerland, operating with 51–100 employees. Specific therapeutic focus, products, and pipeline were not retrievable from available data.
- Ownership category
- akta.pro rank
ADIENNE industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD)
Keywords
Where ADIENNE is headquartered
LocationHeadquarters
- HQ city
- Lugano
- HQ country
- Switzerland
- HQ region
- Europe
Markets served
ADIENNE business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain
ADIENNE product offering
Product offeringCore offering
ADIENNE is a biopharmaceutical company headquartered in Lugano, Switzerland, founded in 2004. The firm develops and manufactures pharmaceutical products, operating with a headcount of 51-100 employees. It functions as a for-profit private biopharma entity focused on producing drug products for the healthcare market.
Differentiator
Problem solved
Functional benefit
Companies that use ADIENNE
Customer profileIdeal customer profiles1 record
ADIENNE technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
ADIENNE partnerships and signals
Strategic signalRecent moves1 record
ADIENNE competitors and assessment
Company assessmentBroad incumbents
- Recordati Rare Diseases: European specialty pharma with a dedicated rare-disease business unit, comparable to ADIENNE in targeting niche specialty therapeutics with premium pricing models and EMEA-led commercialization.
- Shire (now Takeda): Historically a leading specialty/rare-disease biopharma with a focus on small patient populations and premium pricing — relevant comparable for ADIENNE's specialty therapeutic model.
- Alexion (AstraZeneca Rare Disease): Global rare-disease biopharma specializing in highly targeted therapies for small patient populations. Comparable to ADIENNE in product economics, regulatory complexity, and specialty commercial model.
- Jazz Pharmaceuticals: Global specialty biopharma focused on rare diseases and specialty therapeutics, including the historical defibrotide franchise that overlaps directly with ADIENNE's therapeutic areas. Comparable as a specialty pharma commercializer with a similar product-category footprint.
- Swedish Orphan Biovitrum (Sobi): European specialty biopharma focused on rare diseases and specialty care, offering a relevant comparable for revenue model, regulatory pathway, and target patient population dynamics.
Direct peers
- Gentium (now Jazz Pharmaceuticals): Originally an Italian specialty biopharma developing defibrotide for hepatic veno-occlusive disease — directly comparable to ADIENNE's specialty pharma focus and therapeutic category, now operating under Jazz.
- MolMed: European biopharma developing specialty therapeutics including cell & gene therapies for rare and serious diseases, with comparable therapeutic focus and European specialty pharma positioning.
- Helsinn Group: Swiss-based specialty biopharmaceutical company focused on oncology and supportive care, headquartered near Lugano. Closely comparable in geography, therapeutic focus, and private-company specialty pharma positioning.
- Vifor Pharma (CSL Vifor): Swiss specialty biopharma headquartered in the same regional cluster as ADIENNE, focused on niche therapeutics including hematology/cardio-renal. Highly comparable on geography, scale, and therapeutic category.
Emerging players
- Erytech Pharma: European specialty biopharma developing niche oncology and rare-disease therapeutics. Comparable as a smaller, specialty-focused peer with overlapping therapeutic-area ambitions.
Market position
Strengths3 records
Weaknesses3 records
Competitive moat3 records
Key risks4 records
Key highlights4 records
Customer concentration
ADIENNE social profiles
Digital presenceADIENNE financial estimates
Financial estimateRevenue estimate
Valuation estimate
ADIENNE leadership team
Management profileNumber of profiles
Profiles1 record
ADIENNE funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ADIENNE M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ADIENNE
What does ADIENNE do?
ADIENNE is a biopharmaceutical company headquartered in Lugano, Switzerland, founded in 2004. The firm develops and manufactures pharmaceutical products, operating with a headcount of 51-100 employees. It functions as a for-profit private biopharma entity focused on producing drug products for the healthcare market.
When was ADIENNE founded?
ADIENNE was founded in 2004. It employs 51 to 100 people.
Where is ADIENNE based?
ADIENNE is headquartered in Lugano, Switzerland, in the Europe region.
Who are ADIENNE's main competitors?
Broad incumbents on record are Recordati Rare Diseases, Shire (now Takeda), Alexion (AstraZeneca Rare Disease), Jazz Pharmaceuticals and Swedish Orphan Biovitrum (Sobi). Direct peers are Gentium (now Jazz Pharmaceuticals), MolMed, Helsinn Group and Vifor Pharma (CSL Vifor). Erytech Pharma is listed as an emerging player.
Does ADIENNE have an API?
No public API is recorded for ADIENNE.
What industry is ADIENNE in?
ADIENNE's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAIACAD, Endocrinology & Metabolic Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.